05 January 2018

Dr Louise Savic
Consultant Anaesthetist
Leeds Teaching Hospitals Trust
St James' University Hospital
Beckett Street
Leeds
LS9 7TF

Dear Dr Savic

Study title: What is the prevalence, accuracy and impact of drug allergy labelling in the elective surgical population, and how do anaesthetists respond to these labels?

REC reference: 17/LO/2106
IRAS project ID: 232512

The Proportionate Review Sub-committee of the London - Hampstead Research Ethics Committee reviewed the above application via correspondence.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this favourable opinion letter. The expectation is that this information will be published for all studies that receive an ethical opinion but should you wish to provide a substitute contact point, wish to make a request to defer, or require further information, please contact hra.studyregistration@nhs.net outlining the reasons for your request. Under very limited circumstances (e.g. for student research which has received an unfavourable opinion), it may be possible to grant an exemption to the publication of the study.

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval
Ethical opinion

On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).


Where a NHS organisation’s role in the study is limited to identifying and referring potential participants to research sites (“participant identification centre”), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations.

Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database. This should be before the first participant is recruited but no later than 6 weeks after recruitment of the first participant.

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from the HRA. Guidance on where to register is provided on the HRA website.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).
Ethical review of research sites

The favourable opinion applies to all NHS sites taking part in the study, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the favourable opinion”).

Summary of discussion at the meeting

Social or scientific value; scientific design and conduct of the study

The PRS Sub-Committee found the application a little confusing, but after discussion were in agreement that they understood the study enough to review it sufficiently and considered it a worthwhile study.

Approved documents

The documents reviewed and approved were:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copies of advertisement materials for research participants [Advertising poster]</td>
<td>2.0</td>
<td>21 November 2017</td>
</tr>
<tr>
<td>Covering letter on headed paper [Cover letter]</td>
<td>1</td>
<td>23 November 2017</td>
</tr>
<tr>
<td>IRAS Application Form [IRAS_Form_23112017]</td>
<td></td>
<td>23 November 2017</td>
</tr>
<tr>
<td>IRAS Application Form XML file [IRAS_Form_23112017]</td>
<td></td>
<td>23 November 2017</td>
</tr>
<tr>
<td>IRAS Checklist XML [Checklist_23112017]</td>
<td></td>
<td>23 November 2017</td>
</tr>
<tr>
<td>IRAS Checklist XML [Checklist_19122017]</td>
<td></td>
<td>19 December 2017</td>
</tr>
<tr>
<td>Other [Validation Clarification Email]</td>
<td></td>
<td>18 December 2017</td>
</tr>
<tr>
<td>Other [PIL - Healthy Controls]</td>
<td>2</td>
<td>18 December 2017</td>
</tr>
<tr>
<td>Other [DALES Info]</td>
<td>1.0</td>
<td>20 December 2017</td>
</tr>
<tr>
<td>Other [Anaesthetist Survey]</td>
<td></td>
<td>17 December 2017</td>
</tr>
<tr>
<td>Other [Antibiotic Follow Up]</td>
<td></td>
<td>17 December 2017</td>
</tr>
<tr>
<td>Other [Opioid Analgesia Follow Up]</td>
<td></td>
<td>17 December 2017</td>
</tr>
<tr>
<td>Other [Patient Survey -Online]</td>
<td></td>
<td>17 December 2017</td>
</tr>
<tr>
<td>Research protocol or project proposal [Protocol]</td>
<td>3.3</td>
<td>21 November 2017</td>
</tr>
<tr>
<td>Summary CV for Chief Investigator (CI) [CV]</td>
<td>1</td>
<td>18 September 2017</td>
</tr>
</tbody>
</table>

Membership of the Proportionate Review Sub-Committee

The members of the Sub-Committee who took part in the review are listed on the attached sheet.
Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

After ethical review

Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: [http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/](http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/)

HRA Training

We are pleased to welcome researchers and R&D staff at our training days – see details at [http://www.hra.nhs.uk/hra-training/](http://www.hra.nhs.uk/hra-training/)

With the Committee's best wishes for the success of this project.

17/LO/2106 Please quote this number on all correspondence

Yours sincerely

On behalf of
Miss Stephanie Ellis, BEM
Chair

Email: nrescommittee.london-hampstead@nhs.net

Enclosures: List of names and professions of members who took part in the review

“After ethical review – guidance for researchers”

Copy to: Anne Gowing,
Research and Innovation Department
**Committee Members:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Profession</th>
<th>Present</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Rahul Chodhari</td>
<td>Consultant Paediatrician</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Miss Stephanie Ellis, BEM</td>
<td>Former Civil Servant</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Dr Alicia Isabel Etchegoyen</td>
<td>Psychiatrist</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

**Also in attendance:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position (or reason for attending)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miss Ewa Grzegorska</td>
<td>Acting REC Manager</td>
</tr>
<tr>
<td>Miss Nafeesa Khanam</td>
<td>REC Assistant</td>
</tr>
</tbody>
</table>